NDLEA DISMANTLES ABUJA DRUG BUNKS, ARRESTS 132, RECOVERS 220KG ILLICIT SUBSTANCES. (PHOTOS). #PRESS RELEASE.

Image
 NDLEA dismantles Abuja drug bunks, arrests 132, recovers 220kg illicit substances  -Marwa hails operation, vows to sustain crackdown in FCT, other states  In a non-stop two-week offensive action against traffickers and dealers, operatives of the National Drug Law Enforcement Agency (NDLEA) have successfully dismantled several drug joints and bunks within and around the Federal Capital Territory (FCT) Abuja where a total of 132 suspects were arrested and 220 kilograms of assorted illicit substances recovered. The wel-coordinated raids jointly conducted by the Agency's Directorate of Operations and General Investigation (DOGI) and the FCT Strategic Command from llth to 25th April 2026 were launched to dismantle illicit drug hubs contributing to substance abuse, trafficking, and associated criminal activities in the capital city after weeks of intelligence and surveillance across all identified hotspots. Areas where notorious drug joints were raided, dismantled and suspects...

GSK CEO TO RESIGN BY THE END OF THE YEAR. (PHOTO).


 GSK CEO to resign by the end of the year

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down on Dec. 31 after more than eight years at the helm of the London-based drugmaker.

Walmsley, 56, will be succeeded by Luke Miels, currently GSK’s chief commercial officer, the company announced Monday. During her tenure, Walmsley oversaw several strategic initiatives, including the spinoff of the consumer health business Haleon, but the company’s overall performance has underwhelmed investors. GSK shares rose 3.3% to 1,534.50 pence in early trading, making it the top gainer on the London Stock Exchange.

Despite these gains, GSK’s stock has fallen 11% since Walmsley took over on April 1, 2017. Analysts say the company has delivered on financial guidance but continues to experience slow growth. Derren Nathan, head of equity research at U.K.-based Hargreaves Lansdown, noted that while GSK has achieved progress, “the share price performance has been lackluster” and growth rates remain in the single digits.

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).